Lates News

The company Leikai's ustekinumab and ustekinumab (generic name: Migezhu monoclonal antibody) have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's disease in adults and moderate to severe active ulcerative colitis in adults. Ustekinumab (Migezhu monoclonal antibody injection (intravenous infusion)) and ustekinumab (Migezhu monoclonal antibody injection) are a specific IgG4 monoclonal antibody targeting the interleukin-23 (IL-23) p19 subunit, which selectively inhibits the IL-23 pathway regulating the immune inflammatory response driven by it.